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ABSTRACT
Infections caused by gram-negative bacteria
(GNB) resistant to multiple classes of
antibiotics are increasing in many hospitals.
Extended-spectrum b-lactamase
(ESBL)-producing and carbapenem-resistant
Enterobacteriaceae in particular are now
endemic in many parts of the world and
represent a serious public health threat. In this
era, antimicrobial stewardship programs are
essential as targeted and responsible use of
antibiotics improves patient outcomes and
hopefully limits the selective pressure that
drives the further emergence of resistance.
However, some stewardship strategies aimed at
promoting carbapenem-sparing regimens
remain controversial and are difficult to
implement when resistance rates to
non-carbapenem antibiotics are increasing.
Coordinated efforts between stewardship
programs and infection control are essential
for reversing conditions that favor the
emergence and dissemination of
multidrug-resistant GNB within the hospital
and identifying extra-institutional ‘‘feeder
reservoirs’’ of resistant strains such as
long-term care facilities, where colonization is
common despite limited numbers of serious
infections. In settings where ESBL resistance is
endemic, the cost-effectiveness of expanded
infection control efforts and antimicrobial
stewardship is still unknown. Once a patient
has been colonized, selective oral or digestive
decontamination may be considered, but
evidence supporting its effectiveness is limited
in patients who are already colonized or in
centers with high rates of resistance. Moreover,
temporary success at decolonization may be
associated with a higher risk of relapse with
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INTRODUCTION
Treating infections caused by gram-negative
bacteria (GNB) resistant to multiple classes of
antibiotics is an increasing challenge in many
hospitals. Extended-spectrum b-lactamase
(ESBL)-producing and carbapenem-resistant
Enterobacteriaceae (CRE) in particular are now
endemic in many parts of the world and
represent one of the most serious public
health threats [1, 2]. In this context,
antimicrobial stewardship (AMS) programs
play a critical role in improving appropriate
antibiotic use to improve patient outcomes and
reduce the antibiotic selective pressure that
drives the emergence of further resistance.
However, both the efficacy and collateral
impact of many stewardship strategies are not
well documented, starting from the battle
against the overuse of carbapenems in
non-critically ill patients to the use of
carbapenem-sparing regimens also in critically
ill patients in institutions with endemically
high levels ([20%) of ESBL-producing
Enterobacteriaceae.
Herein, we discuss the leading
stewardship-related controversies and infection
control (IC) measures needed to control
infections caused by ESBL- and CR-producing
Enterobacteriaceae. We also discuss recent
efforts from our large teaching hospital to
contain carbapenem resistance and its impact
on other ESBL resistance rates. This article is
based on previously conducted studies and does
not involve any new studies of human or




ESBL-producing GNBs are now a universal
health concern [2]. ESBL production is
frequently accompanied by other resistance
mechanisms that impart cross-resistance to
many other anti-GNB antibiotics, including
aminoglycosides and fluoroquinolones.
Consequently, carbapenems have long been
regarded as the drugs of choice for suspected or
proven serious infections caused by
ESBL-producing organisms [3–6]. Nevertheless,
the increased use of carbapenems driven by the
spread of ESBL-producing Enterobacteriaceae
has contributed to the emergence of
carbapenem-resistant strains, which currently
represent one of the main concerns in the
management of patients with gram-negative
infections [7, 8]. Avoidance of carbapenems for
the treatment of ESBL-producing organisms is
conceptually appealing from the standpoint of
an AMS program, but could increase the risk of
inappropriate treatment of relapse for patients
with serious infections.
b-Lactam/b-lactamase inhibitor combinations
(BLBLIs) such as piperacillin-tazobactam, have
been recommended as an alternative to
carbapenems for ESBL-producing
Enterobacteriaceae if in vitro susceptibility is
documented. Indeed, case-control studies from
several countries have reported that frontline
protocols that utilized piperacillin-tazobactam
instead of cephalosporines or carbapenems were
associatedwith a reduction in the risk of isolation
of ESBL-producing and CRE, without clear
increases in piperacillin-tazobactam resistance
[8, 9].
However, there are some misgivings about
the role of BLBLIs for the treatment of ESBL
Enterobacteriaceae in clinical practice. First,
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BLBLIs may have diminished efficacy against
ESBL-producing Enterobacteriaceae in the
presence of a high bacterial load, known as
the inoculum effect, which has been observed
specifically with piperacillin-tazobactam [10].
Second, pharmacokinetic/pharmacodynamic
(PK/PD) models may support the use of high
doses of piperacillin/tazobactam for
ESBL-producing Escherichia coli, but are much
less encouraging for Klebsiella pneumoniae with
higher minimum inhibitory concentrations
(MICs) [11]. Third, increasing resistance to
BLBLIs in ESBL producers (especially K.
pneumoniae), overexpression of b-lactamases or
complex coresistance mechanisms, including
expression of other enzymes, such as
plasmid-derived AmpC, may compromise the
use of BLBLIs in empirical therapy.
Several cohort studies and a meta-analysis
have suggested BLBLIs are safe and effective for
ESBL-producing Enterobacteriaceae [12–14],
even though prospective clinical studies are
scarce [15, 16]. The most relevant studies are
two observational, well-designed studies on
patients with bloodstream infections (BSIs)
caused by ESBL-producing GNB, which
reached opposite conclusions: according to
Rodrı´guez-Ban˜o et al. [12], BLBLIs were
equivalent to carbapenems for treating
ESBL-producing E. coli, while Tamma et al. [17]
reported that empiric treatment with
piperacillin-tazobactam versus carbapenem was
associated with increased risk of mortality in BSI
caused by ESBL-producing E.coli, Klebsiella spp.
or Proteus spp. These contrasting findings are
probably due to the differences in terms of
etiological agents of BSI (E.coli only versus E.coli,
Klebsiella spp. or Proteus spp.), administered
dosages of piperacillin/tazobactam (higher
doses were used in the study from Spain, 4.5
versus 3.375 g qid) and infection sources ([70%
of BSIs in the Rodrı´guez-Ban˜o et al. [12] study
originated from the urinary tract versus much
more variable infection sources in the study of
Tamma et al. [17]). The impact of the infectious
source on mortality has been highlighted by a
further analysis of the Spanish cohort:
all the patients with BSI arising from the
urinary tract survived irrespective of the
piperacillin-tazobactam MIC, while, in case of
different BSI sources, the outcome was poorer if
the piperacillin-tazobactam MIC was [2 mg/l
[18].
Ideally, the role of BLBLIs versus
carbapenems for the treatment of bloodstream
infection caused by ESBL producers should be
assessed in a large randomized controlled trial.
Such a study is now recruiting patients (the
‘MERINO’ trial; NCT02176122) and aims to be
completed by 2018.
Based on the data described to date, BLBLIs
can represent a reasonable carbapenem-sparing
treatment option for urinary tract infections,
including those causing bacteremia, caused by
ESBL-producing E. coli or, in case of non-severe
infections, from other sites in which the isolate
is susceptible at a low MIC (B2 lg/ml in
the case of piperacillin-tazobactam). If
piperacillin-tazobactam is used, it should be
administered at high doses and using infusion
strategies that maximize the PK/PD parameters
(i.e., t[MIC; loading dose followed by
maintenance doses administered by extended
or continuous infusion) to guarantee an
adequate exposure [19].
Carbapenems would remain the drug of
choice for non-urinary or non-easily drainable
infections (e.g., pneumonia) caused by
ESBL-producing bacteria with complex
resistance patterns, including K.
pneumoniae and multiple b-lactamases.
However, de-escalation of carbapenems,
recently described to be safe and feasible [20],
probably now represents the most relevant and
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cost-effective intervention of any AMS program
aimed to reduce carbapenem exposure. The
actual ‘‘high-speed’’ microbiological turn
around could be a cornerstone for these
strategies, as further described.
The scenario described above will likely
change in the future, owing to the
introduction of novel BLBLIs in clinical
practice [21]. Ceftazidime-avibactam, an
established antipseudomonal cephalosporin
combined with a new b-lactamase inhibitor,
and ceftolozane (a new cephalosporine)
combined with tazobactam have been
approved by the Food and Drug
Administration (FDA) for the treatment of
complicated intraabdominal and urinary tract
infections [22–24]. These drugs could represent
a further alternative to carbapenems to treat
serious infections caused by ESBL-producing
organisms, and this option for placement in
therapy should be considered in the future
hospital formularies. However, resistance to
these newer cephalosporins or advanced
spectrum b-lactamase inhibitors is already
being reported among Enterobacteriaceae [25];
therefore, their judicious use is a key
consideration for stewardship programs.
CARBAPENEM-RESISTANT
ENTEROBACTERIACEAE
Over the last decade, the prevalence of
infections with CRE has increased worldwide
[1], and given the limited therapeutic options
for these infections, they are associated with
high morbidity and mortality. The crude
mortality among patients with CRE infection
is approximately 40% [26, 27]. The most
relevant observational studies on risk factors
for poor outcome in patients with CRE infection
are summarized in Table 1. Predictors of poor
outcome may be divided in three groups: (1)
patient-related factors that included age,
comorbidities and APACHE score; (2)
infection-related factors such as the
pulmonary source, BSI, severe sepsis or septic
shock at infection onset, and isolation of a
colistin-resistant strain; (3) treatment-related
factors with prompt source control and
combination therapy both associated with
better outcome.
Given the limited number of effective and
safe agents, several strategies have been
proposed to treat CRE infections [28–37]. The
currently recommended strategy is
combination antimicrobial regimens for CRE
with the hope that synergistic interactions
between agents will improve bactericidal
activity, suppress the emergence of resistance
and overcome the PK weaknesses of individual
agents. Indeed, several studies have reported
lower mortality rates (0–40%) among patients
who received combination therapy versus
patients receiving meropenem, colistin or
tigecycline monotherapy (40–80%) [29, 33,
36–38].
Unfortunately, the question of which
combination is superior remains unresolved.
In a meta-analysis of 12 retrospective cohort
studies and case series, an advantage for
combination therapy was identified only in
patients classified as receiving ‘‘any
combination’’ [39]. Among the different
combinations, those that included high-dose
carbapenems (i.e., 4–6 g meropenem
administered by extended infusion) were
associated with better outcome in some
studies [29, 36, 37]. In the latest Italian study
[36], a propensity score adjusted model to assess
the impact on outcome of combination therapy
revealed significantly improved survival among
patients receiving a combination regimen that
included a carbapenem. However, the
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protective role of carbapenems was maintained
only for strains with MIC values B8 mg/l,
representing around 30% of isolates in some
settings with endemic carbapenem resistance.
The impact of carbapenem-sparing regimens
on the outcome of CRE has only been
investigated in a few small cohort studies.
Combination regimens with high-dose
tigecycline (100 mg every 12 h) have been
proposed for patients with pulmonary
infections and were associated with better
outcomes than conventional doses of
tigecycline in the treatment of
ventilator-associated pneumonia caused by
multidrug-resistant (MDR) GNB [30]. However,
tigecycline use has been clearly associated with
the emergence of reduced susceptibility to this
drug [40]. In a recent report of 50 patients with
highly resistant CR-K. pneumoniae (all strains
resistant to colistin and with meropenem MIC
[32 mg/l), regimens that included gentamicin,
mostly in combination with other drugs, were
the only combination associated with lower
mortality [41].
The increasing prevalence of
colistin-resistant strains, nearly 40% in some
geographical areas, has required growing use of
unconventional antibiotic combinations for
CR-K. pneumoniae [42, 43]. Colistin plus
rifampin, double carbapenem therapy and
colistin plus double carbapenems have been
proposed based on in vitro studies, animal
models, and case reports or case series [28, 35,
44, 45]. However, the optimal regimen for such
extremely drug-resistant/pan-drug-resistant
(XDR/PDR) strains is still unknown.
Several new antibiotics, recently approved
(i.e., ceftazidime-avibactam) or in development
(RPX7009, plazomycin), have in vitro activity
against CR-K. pneumoniae. Avibactam inhibits
the activities of Ambler class A and C and some
Ambler class D enzymes, restoring the activity
of ceftazidime against ESBL, K. pneumoniae
carbapenemases (KPC) and/or AmpC
b-lactamases and P. aeruginosa. However,
avibactam does not restore the spectrum of
ceftazidime against metallo-b-lactamases (MBL),
Acinetobacter baumannii and most
gram-negative anaerobes. In a recent
surveillance study of 124 CREs (KPC, n = 87;
MBL, n = 13; OXA-48, n = 7), susceptibility
rates to ceftazidime-avibactam for each group
were 100, 0 and 85.7%, respectively [46]. Some
authors also reported the compassionate use of
ceftazidime-avibactam in four patients with
infections due to Klebsiella oxytoca KPC (1) and
K. pneumoniae OXA-48 (3); clinical cure was
achieved in 2/4 (50%) [47].
RAPID DIAGNOSTIC TESTS USED
BY AMS PROGRAMS
As previously affirmed, early discontinuation of
broad-spectrum empirical antimicrobial
regimens is one of the main goals of AMS
programs. Tests for rapid identification of
microorganisms represent a key tool for this
purpose.
Several rapid molecular assays are
commercially available [48–50]. Peptide
nucleic acid fluorescent in situ hybridization
(PNA FISH; AdvanDx, Woburn, MA, USA),
which uses synthetic oligonucleotide
fluorescence-labeled probes that rapidly
hybridize to species-specific ribosomal RNA,
was one of the first. It can identify E. coli, P.
aeruginosa and K. pneumoniae, but its inability to
identify resistance genes in gram-negative
organisms limits its usefulness. Indeed, no
studies have evaluated the clinical impact of
the use of this assay in patients with
gram-negative infections.
Some clinical data are available about the
implementation of another technique,
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matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (MALDI-TOF
MS), as an adjunctive tool to AMS programs.
MALDI-TOF MS is a fast, reliable and
cost-effective test using the technology of
mass spectrometry (ionization and
disintegration of a target molecule). The mass/
charge ratio of the resulting molecular
fragments is compared with those of
well-characterized organisms in a database
[51]. MALDI-TOF MS does not provide
antimicrobial susceptibility data, but its
integration in AMS programs is associated with
a reduction in time to both active and optimal
therapy, length of stay and hospital costs
[52–54]. Also in a challenging population
constituted of 153 patients with BSIs caused
by MDR and/or ESBL-producing GNB,
integrating rapid diagnostics with AMS
improved outcome. Time to effective and
optimal antibiotic therapy was reduced from
89.7 to 32 h (P\0.001) and from 80.9 to 23.2 h
(P\0.001), respectively. Total and intensive
care unit length of stay decreased from 23.3 to
15.3 days (P = 0.0001) and from 16 to 10.7 days
(P = 0.008), respectively. Mortality was lower
(21% versus 8.9%, P = 0.01) during the
intervention period, and the study
intervention was identified as a predictor of
survival [odds ratio (OR), 0.3; 95% confidence
interval (CI) 0.12–0.79] at multivariate logistic
regression [55]. Interestingly, the impact of
MALDI-TOF MS appears to be higher when a
stewardship team manages the results rather
than when the same results are just provided to
the patient’s attending physicians (reduced
time to appropriate therapy in 28.8% and
44.6% of patients, according to the physician’s
choices and stewardship team
recommendations, respectively; P = 0.001) [56].
Multiplex polymerase chain reaction (PCR)
can be used for simultaneous detection of
multiple organisms and resistance markers.
BioFire Diagnostics’ FilmArray blood culture
identification (BCID) panel tests for 24
organisms, including Enterobacter cloacae
complex, E. coli, Klebsiella species, Proteus
species, Serratia marcescens, and antimicrobial
resistance genes, including carbapenem
resistance, are also used for detection.
Nanoparticle Probe Technology (Nucleic
Acid Extraction and PCR Amplification)
Nanosphere’s Verigene blood culture
gram-negative (BC-GN) assay uses nucleic acid
extraction and PCR amplification followed by
hybridization of target DNA to capture
oligonucleotides on a microarray. After
hybridization, signal amplification of
hybridized probes provides an automated
qualitative analysis of results. This test
identifies genus, species and genetic resistance
determinants [KPC, New Deli
metallo-b-lactamases (NDM), CTX-M, Verona
integron-encoded metallo-b-lactamase (VIM),
IMP and OXA b-lactamases genes] of the most
common gram-negative organisms, with an
approximate turnaround time of 2 h from
blood culture positivity [57, 58]. Although
there are no published clinical studies on this
topic, potential advantages of the use of BC-GN
in combination with an AMS approach have
recently been described by Bork et al. [59]. In
their interesting simulation, they evaluated 132
GN-BSI episodes, performed a theoretical
evaluation of the time to effective and optimal
antibiotic therapy based on BC-GN reporting
and AMS team review (intervention) and
compared them with actual antibiotic
administration times obtained from chart
review (controls). Effective and optimal
antibiotic therapy could be achieved an
average of 3.7 h (95% CI 1.3–6.2; P\0.01) and
18.3 h earlier (95% CI 13.3–23.4; P\0.01) in the
intervention group than in the controls [59].
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In settings with epidemic ESBL-producing
and CR-producing Enterobacteriaceae, rapid
microbiologic tests, in particular novel
techniques that allow early identification of
antimicrobial resistance patterns, can represent
a key tool to improve patient outcomes and
antimicrobial use. Microbiologic technologies
must be integrated in AMS programs, as their





In consideration of the steady increase of
occurrence of infections caused by ESBL and
carbapenemase-producing GNB, AMS programs
have been incorporated into IC strategies
designed to prevent the spread of MDR GNB.
IC practitioners similarly support AMS efforts
through monitoring of resistance trends and
outbreaks in the institution, promoting
compliance with hand hygiene, contact and
transmission precautions, supporting education
efforts and assessing adherence to care bundles.
Effective prevention strategies can reduce the
rate of hospital-acquired infections, decrease
the use of additional antibiotics and, in turn,
reduce the rate of MDR GNB.
Guidelines proposed by the European Society
of Clinical Microbiology and Infectious Diseases
(ESCMID) to prevent the diffusion of MDR GNB
infection and colonization [61] identify four
key aims for IC programs: (1) reduction of
direct-contact transmission involving
skin-to-skin contact and physical transfer of
microorganisms to a susceptible host from an
infected or colonized person via hand washing
and wearing contact precautions; (2) early
identification of colonized patients with active
screening (culture) protocols at hospital
admission followed by contact precautions
and physical separation of colonized patients;
(3) monitoring of cleaning performance and use
of dedicated medical equipment for personal
involved in the care of colonized or infected
patients; (4) reduction in antimicrobial pressure
favoring the selection of MDR GNB through
AMS programs.
Similar measures are suggested for
containing the spread of ESBL-producing
strains in healthcare environments. However,
data supporting the effectiveness of these
recommendations, especially active screening
protocols in institutions with endemically high
resistance rates, are more controversial [61].
First, the epidemiology of ESBL-resistance is
generally more complex than
carbapenem-resistance in Enterobacteriacae.
This complexity is compounded by the
sometimes more sporadic nature of ESBL
resistance. Each of these situations will need to
be managed in different ways, depending on the
risk to the patients involved.
When ESBL resistance is endemic to the
institution, intensive IC efforts in the hospital
alone and AMS may not be sufficient to reduce
resistance. In contrast with other MDR bacteria,
ESBL-mediated resistance is suspected to be
primarily spread through the community and
long-term care facilities and less so within
within healthcare-related institutions [62].
Several reports have confirmed the
environmental persistence of ESBL-producing
E. coli in superficial water, wastewaters and
farms [63, 64]. Antibiotic use in livestock as a
growth-promoter appears to be a major
contributing factor, yet controls on the
prescription and use of antibiotics are almost
nonexistent. Additionally, fecal carriage of
ESBLs has been reported in healthy individuals
residing in the community [65, 66]. As a result
of this situation, a considerable proportion of
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patients infected with ESBL-producing strain in
many European and US hospitals come from
the community [67, 68].
Another controversial aspect of the
circulation of the ESBL-producing strain is the
method of transmission. The role of healthcare
diffusion via the hands of healthcare workers
during hospital outbreaks is predominant for K.
pneumoniae strains but less clear for E. coli strains.
In fact, several reports have shown the failure of
contact precautionmeasures alone in preventing
the diffusion of ESBL-producing E. coli during
outbreaks [61, 69]. Moreover, in settings where
contact precautions are not commonly used for
containing the spread of ESBL strains, the rate of
cross-transmission from healthcare workers’
hands appeared to be low [70].
Several studies showed a possible spread of
ESBL- and/or AmpC-producing bacterial strains
transmitted via the food chain or food animal
production environment [71–73]. In this
situation, it is reasonable to assume that a
significant proportion of hospitalized patients
may be colonized without detection before
admission to the hospital and therefore are
not assigned to isolation precautions. Further
studies are needed to assess the cost
effectiveness of a massive implementation of
IC measures to contain the diffusion of ESBLs in
endemic settings.
A clearer understanding of essential IC
strategies has been described for limiting the
spread of CRE. In a seminal study describing the
containment of a country-wide outbreak of
carbapenem-resistant K. pneumoniae in Israeli
hospitals, Schwaber and colleagues [74]
analyzed the impact of guidelines instituted by
the Israeli Ministry of Health in 2007 that
mandated physical separation and dedicated
staffing for hospitalized carriers of CRE.
Adherence to the guidelines was ensured by a
dedicated task force that reviewed all aspects of
IC and new CRE cases, and it intervened with
additional measures when necessary. With the
nationally implemented intervention, the rates
of CRE acquisition were reduced by nearly
fivefold, and the incidence of new infection
relative to carrier prevalence declined
significantly.
At an institutional level, Ciabotaro et al. [75]
described the practical implementation and
impact of the 2007 Israeli guidelines in their
hospital. In the 40 months following
implementation of the CRE patient screening,
cohorting, cleaning, and education program,
the investigators reported a 16-fold reduction in
carbapenemase-resistant K. pneumoniae that was
sustained for 30 months.
We recently performed a quasi-experimental
study from 2010 to 2014 with 30-month
follow-up of a multifaceted IC program
combined with a stewardship initiative to
reduce CRE BSIs in our 1420-bed
university-affiliated hospital. The program,
managed by a dedicated team, required CRE
rectal culture screening for any patient
transferred or admitted to high-risk units,
cohorting or isolating positive patients, and
using dedicated medical equipment and
transport pathways within the hospital,
education programs for patients, staff and
caregivers, and an intensive hygiene program
with a particular focus on hand washing and
room cleaning. In terms of AMS, a coordinated
program promoting carbapenem-sparing
regimens was implemented to reduce selective
antimicrobial pressure. Any prescription of the
above-mentioned drugs was recorded by
pharmacists, who notified the infectious
disease consultants (IDCs) daily through an
ad-hoc alert system. IDCs reviewed each
prescription within 48 h with a bedside patient
evaluation and recommended modifications to
the prescribers whenever indicated.
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Following the IC and AMS intervention, the
incidence rate of CRE BSI (risk reduction 0.96,
0.92–0.99, P = 0.03) and CRE colonization (risk
reduction 0.96, 0.95–0.97; P\0.0001)
decreased over 30 months (Fig. 1). Our analysis
showed this reduction was not coincidental, as
CRE-screening compliance rates were associated
with the observed reduction in the incidence of
CRE carriage in the hospitalized population, as
detected by monthly rectal swab cultures.
Moreover, when average compliance rates with
the screening protocols waned after 20 months
of the program (Fig. 1b), rates of CRE BSI and
positive-rectal swabs rebounded and only
decreased once average screening compliance
rates had been restored above 75% [76].
Support of the regional health authority [77]
and our hospital administration as well as the
strict application of the IC policy were key
elements in the success of the program and the
AMS initiatives. Interestingly, during the
intervention period, we did not observe a
significant decrease in the incidence of BSI due
to ESBL-producing Enterobacteriaceae or other
MDR GNR organisms, highlighting that in the
absence of specific screening for ESBLs, strictly
applied IC procedures for CRE are unlikely to




Nearly 30 years of selective decontamination
studies that included more than 50 randomized
studies and 10 meta-analyses have suggested
that, in general, selective oral decontamination
(SOD) or selective digestive decontamination
Fig. 1 Monthly incidence trends in KPC-carbapenemase
producing K. pneumoniae bloodstream infections (a) and
colonization (b) detected by rectal swab cultures following
introduction of a comprehensive antimicrobial stewardship
and infection control program to limit carbapenem
resistance. Dotted lines represent the monthly incidence
per 10,000 patient days. Solid lines represent the incidence
trends. Bars in panel b indicate monthly compliance rates of
the fraction of patients who were appropriately screened
with rectal cultures for KPC-carbapenemase producing K.
pneumoniae. IRR calculated by segmented Poisson
regression. Despite declining CRE rates, the IRRs of
ESBL-positive Enterobacteriaceae were stable during the
study period (IRR 1.02, 95% CI 0.99–1.04; P = 0.06).
Likewise, we did not observe marked changes in the rates of
MDR among MDR non-fermenting GNB (IRR 1.04, 95%
CI 0.22–1.22, P = 0.132) or vancomycin-resistant
Enterococcus (IRR 0.98, 0.92–1.04; P = 0.57). IRR
Incidence rate ratio, KPC K. pneumoniae carbapenemases
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(SDD) has a favorable effect on mortality from
serious infections in adult patients admitted to
intensive care units (ICUs) [68, 78]. However,
the largest studies were performed in ICUs with
relatively low rates of antibiotic resistance in The
Netherlands, and the efficacy of these
approaches is less certain when used in patients
who are already documented to be colonized
with MDR organisms. Whether these results
translate to settings with higher rates of
endemic MDR GNB is debatable. Indeed, several
observational studies [79–82] and a small
randomized trial [83] from ICUs with higher
resistance rates have reported contradictory
results regarding the benefits of SDD for
decolonization of MDR GNB.
In the last few years, the efficacy and safety
of SDD with non-absorbable antibiotics for the
eradication of CRE carriage were evaluated in
populations with various underlying conditions
[82, 84–87].
The use of oral regimens of colistin and/or
gentamicin has been mainly proposed for some
specific settings such as patients with
hematological malignancies or candidates to
major surgery including solid organ
transplantation (SOT). However, there are
several misgivings about the use of CRE
decolonization. First, the need for
decolonizing SOT candidates is under debate,
mainly for liver transplantation; indeed, the risk
for CRE infection has been shown to be similar
between CRE colonized and noncolonized
candidates [88, 89]. Second, the efficacy of
decolonization was short term [84–86]. Third,
it has been associated with the emergence of
further resistance [82]. In a large randomized
controlled trial performed in The Netherlands,
routine use of SDD protocols of colistin,
tobramycin and amphotericin B prior to
detected colonization with resistant organisms
was associated with a 7% increase in the
recovery of aminoglycoside-resistant organisms
per month [90]. In a retrospective cohort study
performed in surgical ICUs in Germany,
Lubbert and colleagues [82] reported that
gentamicin and colistin SDD achieved
decolonization rates of KPC-2
carbapenemase-producing K. pneumoniae in
6/14 patients (43%), but was associated with a
rapid increase in secondary bacterial resistance
to both antibiotics. Selection of
colistin-resistant strains in particular is a major
concern because it may predispose patients to
infections with pathogens that are untreatable
with currently available antibiotics [91].
Therefore, the potential ecological impact of
SDD and limited benefits suggest that SDD can
only be used with careful microbiological
monitoring for resistance development.
Clearly, more data are needed to define the
role of preemptive versus targeted SOD and SDD
in the management of MDR GNB and its
potential collateral impact on resistance rates
in the ICU or hospital.
CONCLUSIONS
AMS has been defined as ‘‘a marriage of IC and
antimicrobialmanagement finalized to share the
principles of the optimized treatment between
the bench to bedside point of view and the
hospital-wide vision’’ [92]. According to this
definition, in our opinion, the main aims of
stewardship should be: promoting the
appropriate use of antimicrobials to decrease
the spread of infections caused by MDR
organisms without forgetting the patient
outcome.
There are two principal approaches:
restrictive and persuasive. The oldest strategy
is antibiotic restriction or pre-prescription
authorization, which consists of the
requirement for approval of the antibiotic
S76 Infect Dis Ther (2015) 4 (Suppl 1):S65–S83
from an infectious disease specialist. In endemic
settings for ESBL infections, the restriction of
some key antimicrobials may reduce the
antibiotic pressure and rate of resistant
pathogens. For example, a fluoroquinolone
restriction strategy was demonstrated to
increase fluoroquinolone susceptibility within
a short span of 4 months and reduce the overall
rate of ESBL and Clostridium difficile infection
cases [93, 94].
The persuasive strategy usually consists of a
post-prescription review by an infectious disease
specialist of some of the antimicrobials
prescribed by the attending physicians,
providing advice if necessary. The advantage
of this strategy may also comprise the
improvement of the overall appropriateness of
prescription and the opportunity for early
de-escalation [95]. In a study evaluating the
efficacy of an AMS program based on early
carbapenem de-escalation, the patients enrolled
in the program had a comparable clinical
success, fewer adverse effects and a lower
incidence of the development of resistance
compared to controls [20].
Both of these AMS strategies have pros and
cons; when compared in systematic reviews, the
restrictive policy seems to allow more rapid
results, mainly in terms of reducing
antimicrobial consumptions, but these results
are usually limited in the time because of the
general low level of acceptance of this strategy
by prescribers. The second one seems to be less
effective in terms of reducing antimicrobial
consumption, but has the advantage of
improving the prescription appropriateness
with a potential advantage on patient outcome.
Beyond the classical question about the best
strategy between persuasive or restrictive
actions, an important question remains
unanswered: should stewardship programs be
planned in a whole hospital vision or can we
also think about setting-related, disease-related,
drug-related projects? Another advocated limit
of stewardship programs is the relative paucity,
if not the absence, of multicenter studies across
large healthcare systems; however, because the
inter-center variability of clinical settings and
missions is a distinctive feature of any
healthcare system, it seems logical to ask
ourselves which is the primary goal of any
stewardship program: reproducibility or
attainability in relation to the specific unmet
needs of any single institution or organization?
ACKNOWLEDGMENTS
This supplement was not sponsored by outside
commercial interests. No source of funding was
received for this study or publication of this
article. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, take responsibility for the integrity
of the work as a whole, and have given final
approval for the version to be published.
Conflict of interest. PV has been a
consultant for Merck Sharpe and Dhome and
Achaogen. MG, MB, ST and RL have nothing to
disclose.
Compliance with ethics guidelines. This
article is based on previously conducted
studies and does not involve any new studies
of human or animal subjects performed by any
of the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
Infect Dis Ther (2015) 4 (Suppl 1):S65–S83 S77
use, distribution, and reproduction in any med-
ium, provided you give appropriate credit to the
original author(s) and the source, provide a link
to the Creative Commons license, and indicate if
changes were made.
REFERENCES
1. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber
MJ, Daikos GL, Cormican M, et al. Clinical
epidemiology of the global expansion of Klebsiella
pneumoniae carbapenemases. Lancet Infect Dis.
2013;13(9):785–96 (Epub 2013/08/24).
2. Pitout JD, Laupland KB. Extended-spectrum
beta-lactamase-producing Enterobacteriaceae: an
emerging public-health concern. Lancet Infect Dis.
2008;8(3):159–66 (Epub 2008/02/23).
3. Tumbarello M, Sanguinetti M, Montuori E,
Trecarichi EM, Posteraro B, Fiori B, et al.
Predictors of mortality in patients with
bloodstream infections caused
by extended-spectrum-beta-lactamase-producing
Enterobacteriaceae: importance of inadequate
initial antimicrobial treatment. Antimicrob
Agents Chemother. 2007;51(6):1987–94 (Epub
2007/03/28).
4. Paterson DL, Ko WC, Von Gottberg A, Mohapatra S,
Casellas JM, Goossens H, et al. Antibiotic therapy
for Klebsiella pneumoniae bacteremia: implications
of production of extended-spectrum
beta-lactamases. Clin Infect Dis: Off Publ Infect
Dis Soc Am. 2004;39(1):31–7 (Epub 2004/06/19).
5. Endimiani A, Luzzaro F, Brigante G, Perilli M,
Lombardi G, Amicosante G, et al. Proteus mirabilis
bloodstream infections: risk factors and treatment
outcome related to the expression of
extended-spectrum beta-lactamases. Antimicrob
Agents Chemother. 2005;49(7):2598–605 (Epub
2005/06/28).
6. Paterson DL. Recommendation for treatment of
severe infections caused by Enterobacteriaceae
producing extended-spectrum beta-lactamases
(ESBLs). Clin Microbiol Infect. 2000;6(9):460–3.
7. Canton R, Akova M, Carmeli Y, Giske CG,
Glupczynski Y, Gniadkowski M, et al. Rapid
evolution and spread of carbapenemases among
Enterobacteriaceae in Europe. Clin Microbiol
Infect: Off Publ Eur Soc Clin Microbiol Infect Dis.
2012;18(5):413–31.
8. McLaughlin M, Advincula MR, Malczynski M, Qi C,
Bolon M, Scheetz MH. Correlations of antibiotic use
and carbapenem resistance in enterobacteriaceae.
Antimicrob Agents Chemother. 2013;57(10):
5131–3.
9. Livermore DM, Hope R, Reynolds R, Blackburn R,
Johnson AP, Woodford N. Declining cephalosporin
and fluoroquinolone non-susceptibility among
bloodstream Enterobacteriaceae from the UK: links
to prescribing change? J Antimicrob Chemother.
2013;68(11):2667–74.
10. Lopez-Cerero L, Picon E, Morillo C, Hernandez JR,
Docobo F, Pachon J, et al. Comparative assessment




producing Escherichia coli isolates. Clin Microbiol
Infect. 2010;16(2):132–6.
11. Ambrose PG, Bhavnani SM, Jones RN.
Pharmacokinetics-pharmacodynamics of cefepime
and piperacillin-tazobactam against Escherichia coli
and Klebsiella pneumoniae strains producing
extended-spectrum beta-lactamases: report from
the ARREST program. Antimicrob Agents
Chemother. 2003;47(5):1643–6.
12. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E,
Pascual A. Beta-lactam/beta-lactam inhibitor
combinations for the treatment of bacteremia due
to extended-spectrum beta-lactamase-producing
Escherichia coli: a post hoc analysis of prospective
cohorts. Clin Infect Dis: Off Publ Infect Dis Soc Am.
2012;54(2):167–74 (Epub 2011/11/08).
13. Harris PN, Peleg AY, Iredell J, Ingram PR, Miyakis S,
Stewardson AJ, et al. Meropenem versus
piperacillin-tazobactam for definitive treatment of
bloodstream infections due to ceftriaxone
non-susceptible Escherichia coli and Klebsiella spp.
(the MERINO trial): study protocol for a
randomised controlled trial. Trials. 2015;16(1):24
(Epub 2015/01/28).
14. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME.
Carbapenems versus alternative antibiotics for the
treatment of bacteraemia due to Enterobacteriaceae
producing extended-spectrum beta-lactamases: a
systematic review and meta-analysis. J Antimicrob
Chemother. 2012;67(12):2793–803 (Epub
2012/08/24).
15. Harris PN, Tambyah PA, Paterson DL. beta-lactam
and beta-lactamase inhibitor combinations in the
treatment of extended-spectrum beta-lactamase
producing Enterobacteriaceae: time for a
reappraisal in the era of few antibiotic options?
Lancet Infect Dis. 2015;15(4):475–85 (Epub
2015/02/27).
S78 Infect Dis Ther (2015) 4 (Suppl 1):S65–S83
16. Perez F, Bonomo RA. Editorial commentary:
bloodstream infection caused by
extended-spectrum beta-lactamase-producing
Gram-negative bacteria: how to define the best
treatment regimen? Clin Infect Dis: Off Publ Infect
Dis Soc Am. 2015;60(9):1326–9 (Epub 2015/01/
15).
17. Tamma PD, Han JH, Rock C, Harris AD, Lautenbach
E, Hsu AJ, et al. carbapenem therapy is associated
with improved survival compared with
piperacillin-tazobactam for patients with
extended-spectrum beta-lactamase bacteremia.
Clin Infect Dis: Off Publ Infect Dis Soc Am.
2015;60(9):1319–25 (Epub 2015/01/15).
18. Retamar P, Lopez-Cerero L, Muniain MA, Pascual A,
Rodriguez-Bano J. Impact of the MIC of
piperacillin-tazobactam on the outcome
of patients with bacteremia due
to extended-spectrum-beta-lactamase-producing
Escherichia coli. Antimicrob Agents Chemother.
2013;57(7):3402–4 (Epub2013/04/25).
19. Felton TW, Hope WW, Lomaestro BM, Butterfield
JM, Kwa AL, Drusano GL, et al. Population
pharmacokinetics of extended-infusion
piperacillin-tazobactam in hospitalized patients
with nosocomial infections. Antimicrob Agents
Chemother. 2012;56(8):4087–94 (Epub 2012/05/
16).
20. Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM,
et al. Safety and clinical outcomes of carbapenem
de-escalation as part of an antimicrobial
stewardship programme in an ESBL-endemic
setting. J Antimicrob Chemother.
2015;70(4):1219–25 (Epub 2014/12/05).
21. Toussaint KA, Gallagher JC.
Beta-lactam/beta-lactamase inhibitor
combinations: from then to now. Ann
Pharmacother. 2015;49(1):86–98 (Epub 2014/11/
02).
22. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C.
Comparative study of the efficacy and safety of
ceftazidime/avibactam plus metronidazole versus
meropenem in the treatment of complicated
intra-abdominal infections in hospitalized adults:
results of a randomized, double-blind, phase II trial.
J Antimicrob Chemother. 2013;68(5):1183–92
(Epub 2013/02/09).
23. Vazquez JA, Gonzalez Patzan LD, Stricklin D,
Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and
safety of ceftazidime-avibactam versus
imipenem-cilastatin in the treatment of
complicated urinary tract infections, including
acute pyelonephritis, in hospitalized adults: results
of a prospective, investigator-blinded, randomized
study. Curr Med Res Opin. 2012;28(12):1921–31
(Epub 2012/11/14).
24. Bulik CC, Tessier PR, Keel RA, Sutherland CA,
Nicolau DP. In vivo comparison of CXA-101
(FR264205) with and without tazobactam versus
piperacillin-tazobactam using human simulated
exposures against phenotypically diverse
gram-negative organisms. Antimicrob Agents
Chemother. 2012;56(1):544–9 (Epub 2011/11/09).
25. Humphries RM, Yang S, Hemarajata P, Ward KW,
Hindler JA, Miller SA, et al. First report of
ceftazidime-avibactam resistance in a KPC-3
expressing Klebsiella pneumoniae. Antimicrob
Agents Chemother. 2015. doi:10.1128/AAC.01165-
15
26. Viale P, Giannella M, Lewis R, Trecarichi EM,
Petrosillo N, Tumbarello M. Predictors of mortality
in multidrug-resistant Klebsiella pneumoniae
bloodstream infections. Expert Rev Anti-infect
Ther. 2013;11(10):1053–63 (Epub 2013/10/01).
27. Petrosillo N, Giannella M, Lewis R, Viale P.
Treatment of carbapenem-resistant Klebsiella
pneumoniae: the state of the art. Expert Rev
Anti-infect Ther. 2013;11(2):159–77.
28. Bulik CC, Nicolau DP. Double-carbapenem therapy
for carbapenemase-producing Klebsiella pneumoniae.
Antimicrob Agents Chemother. 2011;55(6):3002–4
(Epub 2011/03/23).
29. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I,
Psichogiou M, Argyropoulou A, et al.
Carbapenemase-producing Klebsiella pneumoniae
bloodstream infections: lowering mortality by
antibiotic combination schemes and the role of
carbapenems. Antimicrob Agents Chemother.
2014;58(4):2322–8 (Epub 2014/02/12).
30. De Pascale G, Montini L, Pennisi M, Bernini V,
Maviglia R, Bello G, et al. High dose tigecycline in
critically ill patients with severe infections due to
multidrug-resistant bacteria. Crit Care.
2014;18(3):R90 (Epub 2014/06/03).
31. Hirsch EB, Tam VH. Detection and treatment
options for Klebsiella pneumoniae carbapenemases
(KPCs): an emerging cause of multidrug-resistant
infection. J Antimicrob Chemother.
2011;65(6):1119–25.
32. Jernigan MG, Press EG, Nguyen MH, Clancy CJ,
Shields RK. The combination of doripenem and
colistin is bactericidal and synergistic against
colistin-resistant, carbapenemase-producing
Klebsiella pneumoniae. Antimicrob Agents
Chemother. 2012;56(6):3395–8.
Infect Dis Ther (2015) 4 (Suppl 1):S65–S83 S79
33. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC,
Sandovsky G, Sordillo E, et al. Treatment outcome
of bacteremia due to KPC-producing Klebsiella
pneumoniae: superiority of combination
antimicrobial regimens. Antimicrob Agents
Chemother. 2012;56(4):2108–13.
34. Sbrana F, Malacarne P, Viaggi B, Costanzo S,
Leonetti P, Leonildi A, et al. Carbapenem-sparing
antibiotic regimens for infections caused by
Klebsiella pneumoniae Carbapenemase-producing K.
pneumoniae in Intensive Care Unit. Clin Infect Dis:
Off Publ Infect Dis Soc Am. 2012;56(5):697–700.
35. Tascini C, Tagliaferri E, Giani T, Leonildi A,
Flammini S, Casini B, et al. Synergistic activity of
colistin plus rifampin against colistin-resistant
KPC-producing Klebsiella pneumoniae. Antimicrob
Agents Chemother. 2013;57(8):3990–3 (Epub
2013/06/12).
36. Tumbarello M, Trecarichi EM, De Rosa FG,
Giannella M, Giacobbe DR, Bassetti M, et al.
Infections caused by KPC-producing Klebsiella
pneumoniae: differences in therapy and mortality
in a multicentre study. J Antimicrob Chemother.
2015;70(7):2133–43 (Epub 2015/04/23).
37. Tumbarello M, Viale P, Viscoli C, Trecarichi EM,
Tumietto F, Marchese A, et al. Predictors of
mortality in bloodstream infections caused by
Klebsiella pneumoniae carbapenemase-producing K.
pneumoniae: importance of combination therapy.
Clin Infect Dis: Off Publ Infect Dis Soc Am.
2012;55(7):943–50 (Epub 2012/07/04).
38. Girometti N, Lewis RE, Giannella M, Ambretti S,
Bartoletti M, Tedeschi S, et al. Klebsiella pneumoniae
bloodstream infection: epidemiology and impact of
inappropriate empirical therapy. Medicine.
2014;93(17):298–309 (Epub 2014/11/15).
39. Paul M, Carmeli Y, Durante-Mangoni E, Mouton
JW, Tacconelli E, Theuretzbacher U, et al.
Combination therapy for carbapenem-resistant
Gram-negative bacteria. J Antimicrob Chemother.
2014;69(9):2305–9 (Epub 2014/05/30).
40. van Duin D, Cober ED, Richter SS, Perez F, Cline M,
Kaye KS, et al. Tigecycline therapy for
carbapenem-resistant Klebsiella pneumoniae (CRKP)
bacteriuria leads to tigecycline resistance. Clin
Microbiol Infect: Off Publ Eur Soc Clin Microbiol
Infect Dis. 2014;20(12):O1117–20 (Epub 2014/06/
17).
41. Gonzalez-Padilla M, Torre-Cisneros J,
Rivera-Espinar F, Pontes-Moreno A, Lopez-Cerero
L, Pascual A, et al. Gentamicin therapy for sepsis
due to carbapenem-resistant and colistin-resistant
Klebsiella pneumoniae. J Antimicrob Chemother.
2015;70(3):905–13 (Epub 2014/10/27).
42. Capone A, Giannella M, Fortini D, Giordano A,
Meledandri M, Ballardini M, et al. High rate of
colistin resistance among patients with
carbapenem-resistant Klebsiella pneumoniae
infection accounts for an excess of mortality. Clin
Microbiol Infect: Off Publ Eur Soc Clin Microbiol
Infect Dis. 2013;19(1):E23–30 (Epub 2012/11/10).
43. Monaco M, Giani T, Raffone M, Arena F,
Garcia-Fernandez A, Pollini S, et al. Colistin
resistance superimposed to endemic
carbapenem-resistant Klebsiella pneumoniae: a
rapidly evolving problem in Italy, November 2013
to April 2014. Euro Surveill. 2014;19(42) (Epub
2014/10/31).
44. Giamarellou H, Galani L, Baziaka F, Karaiskos I.
Effectiveness of a double-carbapenem regimen for
infections in humans due to
carbapenemase-producing pandrug-resistant
Klebsiella pneumoniae. Antimicrob Agents
Chemother. 2013;57(5):2388–90 (Epub 2013/02/
27).
45. Shields RK, Nguyen MH, Potoski BA, Press EG, Chen
L, Kreiswirth BN, et al. Doripenem MICs and
ompK36 porin genotypes of sequence type 258,
KPC-producing Klebsiella pneumoniae may predict
responses to carbapenem-colistin combination
therapy among patients with bacteremia.
Antimicrob Agents Chemother.
2015;59(3):1797–801 (Epub 2014/12/24).
46. Biedenbach D, deJonge B, Nichols W, Sahm D.
Activity of ceftazidime-avibactam and comparators
against carbapenemase-producing
Enterobacteriaceae isolated in sampled countries
of the European Union: 2013 INFORM surveillance
programme. In: 25th European congress of clinical
microbriology and infectious diseases (ECCMID
2015). 2015. p. P1293.
47. Loeches-Yague B, Mora-Rillo M, Pan˜o-Pardo J,
Diaz-Pollan B, Ramos J, Rico A, et al.
Compassionate use of ceftazidime-avibactam for
carbapenemase-producing Enterobacteriaceae
(CPE): a single-hospital experience. In: 25th
European congress of clinical microbriology
and infectious diseases (ECCMID 2015). 2015. p.
P1297.
48. Bauer KA, Perez KK, Forrest GN, Goff DA. Review of
rapid diagnostic tests used by antimicrobial
stewardship programs. Clin Infect Dis: Off Publ
Infect Dis Soc Am. 2014;59(Suppl 3):S134–45.
49. Tuite N, Reddington K, Barry T, Zumla A, Enne V.
Rapid nucleic acid diagnostics for the detection of
antimicrobial resistance in Gram-negative bacteria:
is it time for a paradigm shift? J Antimicrob
Chemother. 2014;69(7):1729–33.
S80 Infect Dis Ther (2015) 4 (Suppl 1):S65–S83
50. Kothari A, Morgan M, Haake DA. Emerging
technologies for rapid identification of
bloodstream pathogens. Clin Infect Dis: Off Publ
Infect Dis Soc Am. 2014;59(2):272–8.
51. Tan KE, Ellis BC, Lee R, Stamper PD, Zhang SX,
Carroll KC. Prospective evaluation of a
matrix-assisted laser desorption ionization-time of
flight mass spectrometry system in a hospital
clinical microbiology laboratory for identification
of bacteria and yeasts: a bench-by-bench study for
assessing the impact on time to identification and
cost-effectiveness. J Clin Microbiol.
2012;50(10):3301–8.
52. Huang AM, Newton D, Kunapuli A, Gandhi TN,
Washer LL, Isip J, et al. Impact of rapid organism
identification via matrix-assisted laser desorption/
ionization time-of-flight combined with
antimicrobial stewardship team intervention in
adult patients with bacteremia and candidemia.
Clin Infect Dis: Off Publ Infect Dis Soc Am.
2013;57(9):1237–45.
53. Perez KK, Olsen RJ, Musick WL, Cernoch PL, Davis
JR, Land GA, et al. Integrating rapid pathogen
identification and antimicrobial stewardship
significantly decreases hospital costs. Arch Pathol
Lab Med. 2013;137(9):1247–54.
54. Clerc O, Prod’hom G, Vogne C, Bizzini A, Calandra
T, Greub G. Impact of matrix-assisted laser
desorption ionization time-of-flight mass
spectrometry on the clinical management of
patients with Gram-negative bacteremia: a
prospective observational study. Clin Infect Dis:
Off Publ Infect Dis Soc Am. 2013;56(8):1101–7.
55. Perez KK, Olsen RJ, Musick WL, Cernoch PL, Davis
JR, Peterson LE, et al. Integrating rapid diagnostics
and antimicrobial stewardship improves outcomes
in patients with antibiotic-resistant Gram-negative
bacteremia. J Infect. 2014;69(3):216–25.
56. Tamma PD, Tan K, Nussenblatt VR, Turnbull AE,
Carroll KC, Cosgrove SE. Can matrix-assisted laser
desorption ionization time-of-flight mass
spectrometry (MALDI-TOF) enhance antimicrobial
stewardship efforts in the acute care setting? Infect
Control Hosp Epidemiol. 2013;34(9):990–5.
57. Mancini N, Infurnari L, Ghidoli N, Valzano G,
Clementi N, Burioni R, et al. Potential impact of a
microarray-based nucleic acid assay for rapid
detection of Gram-negative bacteria and resistance
markers in positive blood cultures. J Clin Microbiol.
2014;52(4):1242–5.
58. Hill JT, Tran KD, Barton KL, Labreche MJ, Sharp SE.
Evaluation of the nanosphere Verigene BC-GN
assay for direct identification of gram-negative
bacilli and antibiotic resistance markers from
positive blood cultures and potential impact for
more-rapid antibiotic interventions. J Clin
Microbiol. 2014;52(10):3805–7.
59. Bork JT, Leekha S, Heil EL, Zhao L, Badamas R,
Johnson JK. Rapid testing using the Verigene
Gram-negative blood culture nucleic acid test in
combination with antimicrobial stewardship
intervention against Gram-negative bacteremia.
Antimicrob Agents Chemother.
2015;59(3):1588–95.
60. Holtzman C, Whitney D, Barlam T, Miller NS.
Assessment of impact of peptide nucleic acid
fluorescence in situ hybridization for rapid
identification of coagulase-negative staphylococci
in the absence of antimicrobial stewardship
intervention. J Clin Microbiol. 2011;49(4):1581–2.
61. Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G,
Falcone M, Frank U, et al. ESCMID guidelines for
the management of the infection control measures
to reduce transmission of multidrug-resistant
Gram-negative bacteria in hospitalized patients.
Clin Microbiol Infect: Off Publ Eur Soc Clin
Microbiol Infect Dis. 2014;20(Suppl 1):1–55 (Epub
2013/12/18).
62. Woerther PL, Burdet C, Chachaty E, Andremont A.
Trends in human fecal carriage of
extended-spectrum beta-lactamases in the
community: toward the globalization of CTX-M.
Clin Microbiol Rev. 2013;26(4):744–58 (Epub
2013/10/05).
63. Blaak H, Lynch G, Italiaander R, Hamidjaja RA,
Schets FM, de Roda Husman AM.
Multidrug-resistant and extended spectrum
beta-lactamase-producing Escherichia coli in Dutch
surface water and wastewater. PLoS One.
2015;10(6):e0127752 (Epub 2015/06/02).
64. Brinas L, Moreno MA, Zarazaga M, Porrero C, Saenz
Y, Garcia M, et al. Detection of CMY-2, CTX-M-14,
and SHV-12 beta-lactamases in Escherichia coli
fecal-sample isolates from healthy chickens.
Antimicrob Agents Chemother. 2003;47(6):2056–8
(Epub 2003/05/23).
65. Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F,
Oliver A, Horcajada JP, et al. Community infections
caused by extended-spectrum
beta-lactamase-producing Escherichia coli. Arch
Intern Med. 2008;168(17):1897–902 (Epub
2008/09/24).
66. Canton R, Novais A, Valverde A, Machado E, Peixe
L, Baquero F, et al. Prevalence and spread of
extended-spectrum beta-lactamase-producing
Enterobacteriaceae in Europe. Clin Microbiol
Infect. 2008;14(Suppl 1):144–53 (Epub 2007/12/
25).
Infect Dis Ther (2015) 4 (Suppl 1):S65–S83 S81
67. Leistner R, Meyer E, Gastmeier P, Pfeifer Y, Eller C,
Dem P, et al. Risk factors associated with the
community-acquired colonization of
extended-spectrum beta-lactamase (ESBL) positive
Escherichia Coli. an exploratory case-control study.
PLoS One. 2013;8(9):e74323 (Epub 2013/09/17).
68. Doi Y, Park YS, Rivera JI, Adams-Haduch JM,
Hingwe A, Sordillo EM, et al.
Community-associated extended-spectrum
beta-lactamase-producing Escherichia coli infection
in the United States. Clin Infect Dis.
2013;56(5):641–8 (Epub 2012/11/15).
69. Paterson DL, Singh N, Rihs JD, Squier C, Rihs BL,
Muder RR. Control of an outbreak of infection due
to extended-spectrum beta-lactamase-producing
Escherichia coli in a liver transplantation unit. Clin
Infect Dis. 2001;33(1):126–8 (Epub 2001/06/05).
70. Tschudin-Sutter S, Frei R, Dangel M, Stranden A,
Widmer AF. Rate of transmission of
extended-spectrum beta-lactamase-producing
enterobacteriaceae without contact isolation. Clin
Infect Dis. 2012;55(11):1505–11 (Epub 2012/09/
08).
71. Kojima A, Ishii Y, Ishihara K, Esaki H, Asai T, Oda C,
et al. Extended-spectrum-beta-lactamase-producing
Escherichia coli strains isolated from farm animals
from 1999 to 2002: report from the Japanese
Veterinary Antimicrobial Resistance Monitoring
Program. Antimicrob Agents Chemother.
2005;49(8):3533–7 (Epub 2005/07/29).
72. Kola A, Kohler C, Pfeifer Y, Schwab F, Kuhn K,
Schulz K, et al. High prevalence of
extended-spectrum-beta-lactamase-producing
Enterobacteriaceae in organic and conventional
retail chicken meat, Germany. J Antimicrob
Chemother. 2012;67(11):2631–4 (Epub 2012/08/
08).
73. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart
J, Voets GM, van den Munckhof MP, van
Essen-Zandbergen A, et al. Dutch patients, retail
chicken meat and poultry share the same ESBL
genes, plasmids and strains. Clin Microbiol Infect.
2011;17(6):873–80 (Epub 2011/04/06).
74. Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G,
Rubinovitch B, et al. Containment of a
country-wide outbreak of carbapenem-resistant
Klebsiella pneumoniae in Israeli hospitals via a
nationally implemented intervention. Clin Infect
Dis: Off Publ Infect Dis Soc Am. 2011;52(7):848–55.
75. Ciobotaro P, Oved M, Nadir E, Bardenstein R,
Zimhony O. An effective intervention to limit the
spread of an epidemic carbapenem-resistant
Klebsiella pneumoniae strain in an acute care
setting: from theory to practice. Am J Infect
Control. 2011;39(8):671–7 (Epub 2011/08/26).
76. Viale P, Tumietto F, Giannella M, Bartoletti M,
Tedeschi S, Ambretti S, et al. Impact of a
hospital-wide multifaceted programme for
reducing carbapenem-resistant Enterobacteriaceae
infections in a large teaching hospital in northern
Italy. Clin Microbiol Infect. 2015;21(3):242–7
(Epub 2015/02/07).
77. Gagliotti C, Cappelli V, Carretto E, Marchi M, Pan
A, Ragni P, et al. Control of
carbapenemase-producing Klebsiella pneumoniae: a
region-wide intervention. Euro Surv: bulletin
Europeen sur les maladies transmissibles. Eur
Commun Dis Bull. 2014;19(43). doi:10.2807/1560-
7917.ES2014.19.43.20943 (Epub 2014/11/07).
78. Price R, MacLennan G, Glen J. Selective digestive or
oropharyngeal decontamination and topical
oropharyngeal chlorhexidine for prevention of
death in general intensive care: systematic review
and network meta-analysis. BMJ. 2014;348:g2197
(Epub 2014/04/02).
79. Taylor ME, Oppenheim BA. Selective
decontamination of the gastrointestinal tract as
an infection control measure. J Hosp Infect.
1991;17(4):271–8 (Epub 1991/04/01).
80. Decre D, Gachot B, Lucet JC, Arlet G,
Bergogne-Berezin E, Regnier B. Clinical and
bacteriologic epidemiology of extended-spectrum
beta-lactamase-producing strains of Klebsiella
pneumoniae in a medical intensive care unit. Clin
Infect Dis. 1998;27(4):834–44 (Epub 1998/11/03).
81. Agusti C, Pujol M, Argerich MJ, Ayats J, Badia M,
Dominguez MA, et al. Short-term effect of the
application of selective decontamination of the
digestive tract on different body site reservoir ICU
patients colonized by multi-resistant Acinetobacter
baumannii. J Antimicrob Chemother.
2002;49(1):205–8 (Epub 2001/12/26).
82. Lubbert C, Faucheux S, Becker-Rux D, Laudi S,
Durrbeck A, Busch T, et al. Rapid emergence of
secondary resistance to gentamicin and colistin
following selective digestive decontamination in
patients with KPC-2-producing Klebsiella
pneumoniae: a single-centre experience. Int J
Antimicrob Agents. 2013;42(6):565–70 (Epub
2013/10/09).
83. Brun-Buisson C, Legrand P, Rauss A, Richard C,
Montravers F, Besbes M, et al. Intestinal
decontamination for control of nosocomial
multiresistant gram-negative bacilli. Study of an
outbreak in an intensive care unit. Ann Intern Med.
1989;110(11):873–81.
S82 Infect Dis Ther (2015) 4 (Suppl 1):S65–S83
84. Zuckerman T, Benyamini N, Sprecher H, Fineman
R, Finkelstein R, Rowe JM, et al. SCT in patients
with carbapenem resistant Klebsiella pneumoniae: a
single center experience with oral gentamicin for
the eradication of carrier state. Bone Marrow
Transplant. 2011;46(9):1226–30.
85. Saidel-Odes L, Polachek H, Peled N, Riesenberg K,
Schlaeffer F, Trabelsi Y, et al. A randomized,
double-blind, placebo-controlled trial of selective
digestive decontamination using oral gentamicin
and oral polymyxin E for eradication of
carbapenem-resistant Klebsiella pneumoniae
carriage. Infect Control Hosp Epidemiol.
2012;33(1):14–9.
86. Oren I, Sprecher H, Finkelstein R, Hadad S,
Neuberger A, Hussein K, et al. Eradication of
carbapenem-resistant Enterobacteriaceae
gastrointestinal colonization with nonabsorbable
oral antibiotic treatment: a prospective controlled
trial. Am J Infect Control. 2013;41(12):1167–72
(Epub 2013/11/28).
87. Tascini C, Sbrana F, Flammini S, Tagliaferri E, Arena
F, Leonildi A, et al. Oral gentamicin gut
decontamination for prevention of KPC-producing
Klebsiella pneumoniae infections: relevance of
concomitant systemic antibiotic therapy.
Antimicrob Agents Chemother. 2014;58(4):1972–6
(Epub 2014/01/15).
88. Giannella M, Bartoletti M, Morelli MC, Tedeschi S,
Cristini F, Tumietto F, et al. Risk factors for
infection with carbapenem-resistant Klebsiella
pneumoniae after liver transplantation: the
importance of pre- and posttransplant
colonization. Am J Transplant.
2015;15(6):1708–15 (Epub 2015/03/11).
89. Giannella M, Morelli MC, Cristini F, Ercolani G,
Cescon M, Bartoletti M, et al. Carbapenem-resistant
Klebsiella pneumoniae colonization at liver
transplantation: a management challenge. Liver
Transpl. 2014;20(5):631–3 (Epub 2014/03/29).
90. Oostdijk EA, de Smet AM, Bonten MJ, Dutch
SODSDDtg. Effects of decontamination of the
digestive tract and oropharynx in intensive care
unit patients on 1-year survival. Am J Respir Crit
Care Med. 2013;188(1):117–20.
91. Kollef MH, Micek ST. Rational use of antibiotics in
the ICU: balancing stewardship and clinical
outcomes. JAMA. 2014;312(14):1403–4.
92. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN,
Weinstein RA, Burke JP, et al. Infectious Diseases
Society of America and the Society for Healthcare
Epidemiology of America guidelines for developing
an institutional program to enhance antimicrobial
stewardship. Clin Infect Dis: Off Publ Infect Dis Soc
Am. 2007;44(2):159–77 (Epub 2006/12/19).
93. Sarma JB, Marshall B, Cleeve V, Tate D, Oswald T,
Woolfrey S. Effects of fluoroquinolone restriction
(from 2007 to 2012) on Clostridium difficile
infections: interrupted time-series analysis. J Hosp
Infect. 2015;91(1):74–80 (Epub 2015/07/15).
94. Sarma JB, Marshall B, Cleeve V, Tate D, Oswald T,
Woolfrey S. Effects of fluoroquinolone restriction
(from 2007 to 2012) on resistance in
Enterobacteriaceae: interrupted time-series
analysis. J Hosp Infect. 2015;91(1):68–73 (Epub
2015/07/01).
95. Davey P, Brown E, Charani E, Fenelon L, Gould IM,
Holmes A, et al. Interventions to improve antibiotic
prescribing practices for hospital inpatients.
Cochrane Database Syst Rev. 2013;4:CD003543
(Epub 2013/05/02).
96. Nguyen M, Eschenauer GA, Bryan M, O’Neil K,
Furuya EY, Della-Latta P, et al.
Carbapenem-resistant Klebsiella pneumoniae
bacteremia: factors correlated with clinical and
microbiologic outcomes. Diagn Microbiol Infect
Dis. 2010;67(2):180–4.
97. Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A,
Bonomo RA, et al. Treatment and outcomes in
carbapenem-resistant Klebsiella pneumoniae
bloodstream infections. Diagn Microbiol Infect
Dis. 2011;69(4):357–62.
98. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos
V, Pitiriga V, Ranellou K, et al. Predictors of
mortality in patients with bloodstream infections
caused by KPC-producing Klebsiella pneumoniae and
impact of appropriate antimicrobial treatment. Clin
Microbiol Infect: Off Publ Eur Soc Clin Microbiol
Infect Dis. 2011;17(12):1798–803.
Infect Dis Ther (2015) 4 (Suppl 1):S65–S83 S83
